6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: February 2024

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

On February 7, 2024, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), issued a press release announcing that the U.S. Patent and Trademark Office issued a new patent covering Allocetra^TM^, Enlivex’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product’s composition and manufacturing method. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: February 7, 2024

2 ****

Exhibit 99.1

Enlivex Announces Issuance of New U.S. PatentCovering Allocetra Cells and Their Manufacturing Method

Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE)– Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering Allocetra^TM^, the Company’s immunotherapy product candidate. The new patent is expected to provide added intellectual property protection in the United States for the product’s composition and manufacturing method.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra^TM^, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This pressrelease contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,”“will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,”“intends,” “estimates,” “suggests,” “has the potential to” and other words of similarmeaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinicalexperiments, the effectiveness of, and market opportunities for, ALLOCETRA^TM^ programs. All such forward-looking statementsare made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautionedthat forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including therisks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in developmentmay fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketingof these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantialor any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-lookingstatements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and othertrials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials.The development of any products using the ALLOCETRA^TM^ product line could also be affected by a number of other factors,including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, theimpact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietaryrights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider theeconomic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and ExchangeCommission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertakeany obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO

Enlivex Therapeutics, Ltd.

shachar@enlivexpharm.com